Incyte Corp at JPMorgan Healthcare Conference Transcript
All right. Thank you. Good morning, everyone. Keep this train rolling here. My name is Cory Kasimov. I'm the senior large-cap biotech analyst at JPMorgan, and it's my pleasure to introduce our next company Incyte. Here to present for Incyte is the CEO, Hervé Hoppenot. And please note that following Hervé's presentation, there's a breakout just across the hall in the Georgian Room. So with that, turn it over to Hervé.
© -
Guys, thank you. Thank you, Cory. Welcome, everybody, this morning. So first, let me say that I will be making some forward-looking statements in this presentation, and you should refer to our SEC documents. So what I would like to do is to start with the big picture on Incyte. And from the right of the slide to the left, what you see is that we have a very productive and innovative discovery team or teams in small molecule, in antibodies and in bispecific, we have a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
